Attovia registers Phase 2 trial of ATTO-1310 for chronic pruritus of unknown origin

Attovia Therapeutics had one registry update this week, a new Phase 2 study of its drug ATTO-1310.

• ATTO-1310, Phase 2, chronic pruritus of unknown origin (CPUO): registered on 2026-09-22 as "not yet recruiting," with an estimated start of 2026-12-21. The trial is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study evaluating ATTO-1310 in adults with chronic pruritus/itch of unknown origin¹, planning to enroll 300 participants (estimated)¹. The primary outcome is the proportion of participants achieving a 4-point or greater improvement from baseline in the Worst Itch Numerical Rating Scale at Week 12, on a scale from zero (no itch) to 10 (worst possible itch)¹.